PA-SYNERGIS-SOFTWARE
28.10.2020 13:23:34 CET | Business Wire | Press release
Synergis Software , a global leader in engineering information management and product data management (PDM), today announced that its flagship product, Adept, has earned 21 top placements in G2 Crowd ’s Fall 2020 Grid Reports.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005422/en/
The reports, which are based on real customer reviews, highlight Adept’s leadership in ease of use, ease of setup, fastest implementation, best support and best relationship as some of the key differentiators compared to other products on the market.
Adept earned Leader status in Product Data Management (PDM) and Enterprise Content Management (ECM), and High Performer status in Construction Drawing Management.
“We're committed to helping clients become more efficient, secure and collaborative, and reports like this help us understand what we're doing well and how we can improve,” said Scott Lamond, vice president of marketing at Synergis Software. “We’re energized and honored that the voice of the customer has us ranked at the top of our field.”
Adept also achieved an exceptional 77 on the G2 Net Promoter Scorecard (NPS).
According to G2, “The purpose of NPS is to gauge customer loyalty to a brand, and how likely they are to recommend your product to a peer. An NPS at-or-above 70 is considered “world class.” Essentially, this means nearly every customer would advocate for that product."
Here’s what some Adept customers had to say:
- “Data is the cornerstone of any business today and not securing it is a huge risk. If you want to do it right and do it well, the Adept platform is the gold-standard.”
- “No other software company anywhere works as closely with their customers. For a system that your business cannot operate without, this is invaluable.”
- “An immediate 30% gain in user efficiency”
Adept earned top honors in the following rankings:
Product Data Management - Best Usability, Easiest Setup, Fastest Implementation, Most Implementable, Ease of Administration, Ease of Doing Business, Quality of Support, Best Relationship, Most Likely to Recommend, Highest Net Promoter Score
Construction Drawing Management - Easiest to Use, Best Meets Requirements, Easiest Setup, Best Support, Highest User Adoption, Easiest to do Business With, Product Going in the Right Direction, Most likely to Recommend, Highest Net Promoter Score
Enterprise Content Management - Ease of Doing Business With, Best Search Capabilities
To see how Adept stacks up, download the full comparison report .
You can read more customer feedback on G2’s Adept review page .
Learn more about G2’s scoring methodology here .
About Synergis Software
Synergis Software is the leader in engineering document management and product data management, helping businesses become more efficient, secure and collaborative. The flagship product, Adept, gets everyone on the same page, simplifying the way organizations find, manage, share and integrate enterprise content. Adept streamlines engineering change management, protects intellectual property, and provides data insights to improve decision making. Adept is integrated with AutoCAD®, Autodesk Inventor®, SolidWorks® and MicroStation®, and has been battle tested by engineers for over 30 years in customers like Dow Chemical, Con Edison, General Mills, Bayer, and Nucor Steel.
G2 Crowd
G2 Crowd , the world's leading business solution review platform, leverages more than 790,000 user reviews to drive better purchasing decisions. G2 aims to bring authenticity and transparency to the business marketplace by leveraging peer reviews, satisfaction scores, and synthesized social data.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005422/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
